429 related articles for article (PubMed ID: 19754359)
1. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between IGF-1R and other tumor promoting pathways.
Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
4. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
8. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
[TBL] [Abstract][Full Text] [Related]
10. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
11. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
Singh I; Amin H; Rah B; Goswami A
Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
[TBL] [Abstract][Full Text] [Related]
13. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.
Adams TE; McKern NM; Ward CW
Growth Factors; 2004 Jun; 22(2):89-95. PubMed ID: 15253384
[TBL] [Abstract][Full Text] [Related]
14. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Saxena NK; Taliaferro-Smith L; Knight BB; Merlin D; Anania FA; O'Regan RM; Sharma D
Cancer Res; 2008 Dec; 68(23):9712-22. PubMed ID: 19047149
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
17. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
18. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
Tandon R; Senthil V; Nithya D; Pamidiboina V; Kumar A; Malik S; Chaira T; Diwan M; Gupta P; Venkataramanan R; Malik R; Das B; Dastidar SG; Cliffe I; Ray A; Bhatnagar PK
Eur J Pharmacol; 2013 Jul; 711(1-3):19-26. PubMed ID: 23639757
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
van der Meel R; Oliveira S; Altintas I; Heukers R; Pieters EH; van Bergen en Henegouwen PM; Storm G; Hennink WE; Kok RJ; Schiffelers RM
Mol Pharm; 2013 Oct; 10(10):3717-27. PubMed ID: 23889133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
